canertinib dihydrochloride has been researched along with nsc 350386 in 1 studies
| Studies (canertinib dihydrochloride) | Trials (canertinib dihydrochloride) | Recent Studies (post-2010) (canertinib dihydrochloride) | Studies (nsc 350386) | Trials (nsc 350386) | Recent Studies (post-2010) (nsc 350386) |
|---|---|---|---|---|---|
| 31 | 13 | 6 | 16 | 0 | 0 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barasoain, I; Briand, C; de Ines, C; Garcia, P; Leynadier, D; Peyrot, V; Rener, GA; Temple, C | 1 |
1 other study(ies) available for canertinib dihydrochloride and nsc 350386
| Article | Year |
|---|---|
Inhibition of microtubules and cell cycle arrest by a new 1-deaza-7,8-dihydropteridine antitumor drug, CI 980, and by its chiral isomer, NSC 613863.
Topics: Animals; Antineoplastic Agents; Carbamates; Cell Cycle; Cell Line; Humans; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Mice; Microtubule Proteins; Microtubules; Pyrazines; Pyridines; Tumor Cells, Cultured | 1994 |